容积PET疗效评估优于传统标准用于接受高剂量帕博利珠单抗治疗的恶性间皮瘤患者
回顾性分析27例化疗耐药恶性胸膜或腹膜间皮瘤患者,接受高剂量帕博利珠单抗(10 mg/kg,第1天,每2周)治疗,基线与随访行18F-FDG PET/CT。基于PERCIST代谢肿瘤体积的缓解可预测总生存和无进展生存(P<0.01),而RECIST 1.1、改良RECIST、PERCISTSULpeak及PD-L1表达均未预测生存。
要点
- PERCISTMTV缓解率30%,预测OS和PFS延长(P<0.01)。
- RECIST、改良RECIST、PERCISTSULpeak缓解率分别为7%、7%、30%,均未预测生存。
- PD-L1表达与预后无关。
核心结论
- 18F-FDG PET代谢体积缓解可预测接受高剂量帕博利珠单抗治疗的恶性间皮瘤患者的生存。
- 作者认为这些结果应促使未来3期临床试验纳入PET疗效评估。
研究设计与样本
- 回顾性分析27例化疗耐药恶性胸膜或腹膜间皮瘤患者,基线与随访行18F-FDG PET/CT。
- 高剂量帕博利珠单抗10 mg/kg,第1天,每2周,参照KEYNOTE-028试验。
- 分别应用RECIST 1.1、改良RECIST、PERCISTSULpeak和PERCISTMTV在CT和PET影像中划分缓解者。
- 采用Kaplan-Meier和log-rank分析比较缓解者与非缓解者的PFS和OS。
- 评估PD-L1表达状态并研究其与结局的关联。
主要发现
- 27例患者基线和至少4周期帕博利珠单抗后行18F-FDG PET/CT。
- 中位PFS为3.4个月,中位OS为15.1个月。
- 基于RECIST、改良RECIST、PERCISTSULpeak和PERCISTMTV的缓解率分别为7%、7%、30%和30%。
- PERCISTMTV缓解预测OS或PFS延长(P<0.01),其他影像标准和PD-L1表达均未预测。
关键数值与推荐
- RECIST 1.1缓解率7%。
- 改良RECIST缓解率7%。
- PERCISTSULpeak缓解率30%。
- PERCISTMTV缓解率30%。
- PERCISTMTV缓解预测OS或PFS延长(P<0.01)。
临床怎么用
- 作者认为这些结果应促使未来3期临床试验纳入PET疗效评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fixed-dose pembrolizumab (200 mg absolute, day 1, every 3 wk) for the treatment of malignant pleural mesothelioma did not result in survival benefit in the phase 3 PROMISE-meso trial compared with second-line chemotherapy. Because of lack of validated imaging response criteria, responder subgroups with potential survival benefit have not yet been identified. Here, we administered high-dose pembrolizumab (10 mg/kg, day 1, every 2 wk) considering the KEYNOTE-028 trial and assessed the prognostic value of PET metabolic response in patients with chemotherapy-resistant malignant mesothelioma of the pleura or peritoneum. Methods: Data from 27 patients with baseline and follow-up 18F-FDG PET/CT imaging were retrospectively analyzed. RECIST, version 1.1; modified RECIST; and PERCIST using both tumor lesion metabolic activity in a 1 cm3 spheric region of interest of up to 5 target lesions (PERCISTSULpeak) and metabolic tumor volume PERCIST (PERCISTMTV) were applied separately to categorize responders in CT and PET imaging studies. Progression-free survival (PFS) and overall survival (OS) were compared between responders and nonresponders using Kaplan-Meier and log-rank analyses. Programmed cell death protein 1 ligand expression status was assessed, and its association with outcome was investigated. Results: Twenty-seven patients had 18F-FDG PET/CT imaging at baseline and after at least 4 cycles pembrolizumab. Median PFS and OS were 3.4 and 15.1 mo, respectively. Response rates were 7%, 7%, 30%, and 30% based on RECIST, modified RECIST, PERCISTSULpeak, and PERCISTMTV response criteria, respectively. Response according to PERCISTMTV predicted prolonged OS or PFS (P < 0.01), whereas all other imaging criteria and programmed cell death protein 1 ligand expression did not. Conclusion:18F-FDG PET metabolic volume response predicts survival in patients with malignant mesothelioma receiving high-dose pembrolizumab. These results should prompt inclusion of PET response assessment in future phase 3 clinical trials.
引用
- Ferdinandus J, Barbato F, Chodyla M, et al. Volumetric PET Response Assessment Outperforms Conventional Criteria in Patients Receiving High-Dose Pembrolizumab for Malignant Mesothelioma. J Nucl Med. 2020. PMID: 32532926. doi:10.2967/jnumed.120.245803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。